Full Press Release Details
Schr dinger Reports Strong First Quarter 2025 Financial Results
First Quarter Total Revenue of $59.6 Million, Software Revenue of $48.8 Million
Initial SGR-1505 Phase 1 Clinical Data to be Presented in June
Maintains 2025 Financial Guidance
New York, May 7, 2025 - Schr dinger, Inc. (Nasdaq SDGR) today announced financial results for the quarter ended March 31, 2025.
"We are very pleased with Schr dinger's performance in the first quarter of 2025, with strong software and drug discovery revenue growth. Our proprietary pipeline is progressing, and we are looking forward to reporting initial data from the Phase 1 clinical study of SGR-1505 next month," said Ramy Farid, Ph.D., chief executive officer of Schr dinger. "More broadly, the pharmaceutical industry and even regulatory agencies are seeking to increase usage of computational solutions in R D, and we continue to fortify our position as a scientific powerhouse in this field. With our growing software business and advancing pipeline of collaborative and proprietary programs, we believe we have a solid foundation that positions us for long-term growth."
First Quarter 2025 Financial Results
Total revenue for the first quarter increased 63% to $59.6 million, compared to $36.6 million in the first quarter of 2024.
Software revenue for the first quarter increased 46% to $48.8 million, compared to $33.4 million in the first quarter of 2024. The increase was primarily due to early renewals by large customers as well as increases in hosted contracts and contribution revenue.
Drug discovery revenue was $10.7 million for the first quarter, compared to $3.2 million in the first quarter of 2024. First quarter 2025 drug discovery revenue included the recognition of $5.7 million from the company's collaboration with Novartis.
Software gross margin was 72% for the first quarter, compared to 76% in the first quarter of 2024, primarily reflecting the costs associated with the company's predictive toxicology initiative.
Operating expenses were $82.0 million for the first quarter, compared to $86.3 million for the first quarter of 2024. The decrease was primarily due to lower R D expenses.
Other expense was $8.9 million for the first quarter, which included changes in fair value of equity investments and interest income expense, compared to other income of $13.2 million for the first quarter of 2024.
Net loss for the first quarter was $59.8 million, compared to $54.7 million in the first quarter of 2024.
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2025 | 2024 | % Change | |||||||
| (in millions) | |||||||||
| Total revenue | $ | 59.6 | $ | 36.6 | 63% | ||||
| Software revenue | 48.8 | 33.4 | 46% | ||||||
| Drug discovery revenue | 10.7 | 3.2 | 237% | ||||||
| Software gross margin | 72 | % | 76 | % | |||||
| Operating expenses | $ | 82.0 | $ | 86.3 | (5.0)% | ||||
| Other (expense) income | $ | (8.9) | $ | 13.2 | - | ||||
| Net loss | $ | (59.8) | $ | (54.7) | - |
For the three months ended March 31, 2025, Schr dinger reported a net loss of $59.8 million, compared to a net loss of $54.7 million for the three months ended March 31, 2024.
For the three months ended March 31, 2025, Schr dinger reported a non-GAAP net loss of $46.7 million, compared to a non-GAAP net loss of $62.4 million for the three months ended March 31, 2024. See "Non-GAAP Information" below and the table at the end of this press release for a reconciliation of non-GAAP net loss to GAAP net loss.
2025 Financial Outlook
As of May 7, 2025, Schr dinger maintained its previously issued financial guidance for the fiscal year ending December 31, 2025
Software revenue growth is expected to range from 10% to 15%.
Drug discovery revenue is expected to range from $45 million to $50 million.
Software gross margin is expected to range from 74% to 75%.
Operating expense growth in 2025 is expected to be less than 5%.
Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024.
For the second quarter of 2025, software revenue is expected to range from $38 million to $42 million.
Proprietary and Collaborative Pipeline
Schr dinger continues to progress the Phase 1 clinical study of SGR-1505, the company's MALT1 inhibitor, in patients with relapsed refractory B-cell malignancies and expects to report initial clinical data from the trial in June.
Schr dinger is continuing to progress the Phase 1 clinical study of SGR-2921, its CDC7 inhibitor, in patients with AML and myelodysplastic syndrome (MDS). The company expects to report initial data from this trial at a medical meeting in the second half of 2025.
Schr dinger is continuing to progress the Phase 1 clinical study of SGR-3515, the company's Wee1 Myt1 co-inhibitor, in patients with advanced solid tumors. Initial clinical data from this study are expected in the second half of 2025. In April, Schr dinger presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting demonstrating that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors.
Also at the AACR Annual Meeting, Schr dinger presented initial preclinical data for SGR-4174, the company's investigational SOS1 inhibitor. The preclinical data demonstrated that SGR-4174 exhibited potent and selective SOS1 inhibition and has strong tumor growth inhibition as a monotherapy and in combination with MEK or KRAS inhibitors.
In April, the company issued a statement following the FDA's announcement outlining plans to reduce existing animal testing requirements for monoclonal antibodies and other drugs with new approaches, including computation. Schr dinger is advancing its predictive toxicology initiative focused on small molecules, which is expected to be available to customers in the second half of 2025. The company currently offers computational solutions for small molecules and biologics that can be used to evaluate selectivity and the potential for off-target interactions.
In March, Schr dinger scientists published research in Nature Communications describing a novel, computational crystal structure prediction (CSP) method that predicts crystal polymorphs with a high degree of accuracy and reliability. The ability to quickly and accurately predict crystal polymorphs has important applications for drug formulation.
In March, Schr dinger appointed Bridget van Kralingen to its Board of Directors. Ms. van Kralingen brings more than 35 years of experience leading and growing global technology solution and software businesses and is currently a senior partner at Motive Partners, an investment firm focused on technology-enabled companies. Prior to Motive Partners, Ms. van Kralingen spent nearly 18 years in a variety of executive roles at IBM, including as chief executive senior vice president of IBM Global Markets and as chief executive of IBM's Industry Platforms software division.
Webcast and Conference Call Information
Schr dinger will host a conference call to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 4 30 p.m. ET. The live webcast can be accessed under "News Events" in the investors section of Schr dinger's website, https ir.schrodinger.com news-and-events event-calendar. To participate in the live call, please register for the call here. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will receive the dial-in information. The archived webcast will be available on Schr dinger's website for approximately 90 days following the event.
Non-GAAP Information
Included in this press release is certain financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The company presents non-GAAP net income (loss) and non-GAAP net income (loss) per share, which exclude gains and losses on equity investments, changes in fair value of equity investments, and income tax benefits and expenses. Adjusting net income to exclude the impact of these items results in a financial presentation for the company without the impact of our equity investments and tax benefits and expenses. Management believes non-GAAP net income (loss) and non-GAAP net income (loss) per share are useful measures for investors, taken in conjunction with the company's GAAP financial statements because they provide greater period-over-period comparability with respect to the company's operating performance, by excluding non-cash mark-to-market and other valuation adjustments for the company's equity investments, non-recurring cash distributions from the company's equity investments and the tax impact of these distributions that are not reflective of the ongoing operating performance of the business. However, the non-GAAP measures should be considered only in addition to, not as a substitute for or as superior to, net income (loss) and net income (loss) per share or other financial measures prepared in accordance with GAAP.
Other companies in Schr dinger's industry may calculate non-GAAP net income (loss) and non-GAAP net income (loss) per share, differently than we do, limiting their usefulness as comparative measures. For a reconciliation of non-GAAP net income (loss) and non-GAAP net income (loss) per share to GAAP net income (loss) and GAAP net income (loss) per share, respectively, please refer to the tables at the end of this press release.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding Schr dinger's expectations about the speed and capacity of its computational platform, its financial outlook for the fiscal year ending December
31, 2025 and second quarter ending June 30, 2025, its plans to continue to invest in research and its strategic plans to accelerate the growth of its software business and advance its collaborative and proprietary drug discovery programs, the long-term potential of its business, its ability to improve and advance the science underlying its platform, including the ability to predict off-target activity, its ability to improve drug discovery and the timing during which the predictive toxicology initiative's technology will become available to software customers and collaborators, the initiation, timing, progress, and results of its proprietary drug discovery programs and product candidates and the drug discovery programs and product candidates of its collaborators, the clinical potential and favorable properties of its MALT1, CDC7, Wee1 Myt1, and SOS1 inhibitors, including SGR-1505, SGR-2921, SGR-3515, and SGR-4174, the clinical potential and favorable properties of its collaborators' product candidates, as well as expectations related to the use of its cash, cash equivalents and marketable securities. Statements including words such as "aim," "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goal," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schr dinger's current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schr dinger's control, including the demand for its software platform, its ability to further develop its computational platform, its reliance upon third-party providers of cloud-based infrastructure to host its software solutions, factors adversely affecting the life sciences industry, fluctuations in the value of the U.S. dollar and foreign currencies, its reliance upon its third-party drug discovery collaborators, the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of IND submissions, clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and other risks detailed under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 7, 2025, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schr dinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.
Matthew Luchini (Investors)
matthew.luchini schrodinger.com
Allie Nicodemo (Media)
allie.nicodemo schrodinger.com
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except for share and per share amounts)
| Three Months Ended March 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Revenues | |||||||||||
| Software products and services | $ | 48,816 | $ | 33,415 | |||||||
| Drug discovery | 10,735 | 3,183 | |||||||||
| Total revenues | 59,551 | 36,598 | |||||||||
| Cost of revenues | |||||||||||
| Software products and services | 13,522 | 7,976 | |||||||||
| Drug discovery | 14,905 | 9,732 | |||||||||
| Total cost of revenues | 28,427 | 17,708 | |||||||||
| Gross profit | 31,124 | 18,890 | |||||||||
| Operating expenses | |||||||||||
| Research and development | 45,844 | 50,611 | |||||||||
| Sales and marketing | 10,367 | 10,171 | |||||||||
| General and administrative | 25,802 | 25,541 | |||||||||
| Total operating expenses | 82,013 | 86,323 | |||||||||
| Loss from operations | (50,889) | (67,433) | |||||||||
| Other (expense) income | |||||||||||
| Gain on equity investments | - | - | |||||||||
| Change in fair value of equity investments | (13,095) | 8,137 | |||||||||
| Other income | 4,204 | 5,028 | |||||||||
| Total other (expense) income | (8,891) | 13,165 | |||||||||
| Loss before income taxes | (59,780) | (54,268) | |||||||||
| Income tax expense | 28 | 456 | |||||||||
| Net loss | $ | (59,808) | $ | (54,724) | |||||||
| Net loss per share of common and limited common stockholders, basic and diluted | $ | (0.82) | $ | (0.76) | |||||||
| Weighted average shares used to compute net loss per share of common and limited common stockholders, basic and diluted | 73,057,916 | 72,291,134 |
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except for share and per share amounts)
| Assets | March 31, 2025 | December 31, 2024 | |||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 325,997 | $ | 147,326 | |||
| Restricted cash | 11,764 | 15,331 | |||||
| Marketable securities | 174,301 | 204,798 | |||||
| Accounts receivable, net of allowance for doubtful accounts of $210 and $210 | 20,347 | 235,692 | |||||
| Unbilled and other receivables, net of allowance for unbilled receivables of $120 and $100 | 25,973 | 19,641 | |||||
| Prepaid expenses | 12,562 | 12,205 | |||||
| Total current assets | 570,944 | 634,993 | |||||
| Property and equipment, net | 22,937 | 24,196 | |||||
| Equity investments | 30,113 | 43,208 | |||||
| Goodwill | 4,791 | 4,791 | |||||
| Right of use assets - operating leases | 109,661 | 111,883 | |||||
| Other assets | 4,586 | 4,155 | |||||
| Total assets | $ | 743,032 | $ | 823,226 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities | |||||||
| Accounts payable | 11,861 | $ | 10,666 | ||||
| Accrued payroll, taxes, and benefits | 21,494 | 42,110 | |||||
| Deferred revenue | 105,458 | 111,944 | |||||
| Lease liabilities - operating leases | 16,755 | 16,755 | |||||
| Other accrued liabilities | 9,904 | 10,272 | |||||
| Total current liabilities | 165,472 | 191,747 | |||||
| Deferred revenue, long-term | 104,496 | 108,814 | |||||
| Lease liabilities - operating leases, long-term | 99,405 | 101,074 | |||||
| Other liabilities, long-term | 155 | 146 | |||||
| Total liabilities | 369,528 | 401,781 | |||||
| Stockholders' equity | |||||||
| Preferred stock, $0.01 par value. Authorized 10,000,000 shares zero shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | - | - | |||||
| Common stock, $0.01 par value. Authorized 500,000,000 shares 64,179,002 and 63,710,409 shares issued and outstanding at March 31, 2025 and December 31, 2024 , respectively | 642 | 637 | |||||
| Limited common stock, $0.01 par value. Authorized 100,000,000 shares 9,164,193 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 92 | 92 | |||||
| Additional paid-in capital | 958,029 | 946,037 | |||||
| Accumulated deficit | (585,349) | (525,541) | |||||
| Accumulated other comprehensive income | 90 | 220 | |||||
| Total stockholders' equity | 373,504 | 421,445 | |||||
| Total liabilities and stockholders' equity | $ | 743,032 | $ | 823,226 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Three Months Ended March 31, | |||||||||
| 2025 | 2024 | ||||||||
| Cash flows from operating activities | |||||||||
| Net loss | $ | (59,808) | $ | (54,724) | |||||
| Adjustments to reconcile net loss to net cash used in operating activities | |||||||||
| Gain on equity investments | - | - | |||||||
| Fair value adjustments of equity investments | 13,095 | (8,137) | |||||||
| Depreciation and amortization | 1,589 | 1,436 | |||||||
| Stock-based compensation | 11,574 | 12,218 | |||||||
| Noncash investment accretion | (861) | (2,683) | |||||||
| Decrease (increase) in assets | |||||||||
| Accounts receivable, net | 215,345 | 46,153 | |||||||
| Unbilled and other receivables | (6,332) | (2,657) | |||||||
| Reduction in the carrying amount of right of use assets - operating leases | 2,222 | 2,152 | |||||||
| Prepaid expenses and other assets | (788) | (2,559) | |||||||
| Increase (decrease) in liabilities | |||||||||
| Accounts payable | 1,344 | (7,150) | |||||||
| Accrued payroll, taxes, and benefits | (20,616) | (12,214) | |||||||
| Deferred revenue | (10,804) | (7,761) | |||||||
| Lease liabilities - operating leases | (1,669) | (1,967) | |||||||
| Other accrued liabilities | (228) | (1,383) | |||||||
| Net cash provided by (used in) operating activities | 144,063 | (39,276) | |||||||
| Cash flows from investing activities | |||||||||
| Purchases of property and equipment | (596) | (4,095) | |||||||
| Purchases of marketable securities | (27,556) | (37,126) | |||||||
| Proceeds from maturity of marketable securities | 58,784 | 46,300 | |||||||
| Net cash provided by investing activities | 30,632 | 5,079 | |||||||
| Cash flows from financing activities | |||||||||
| Issuances of common stock upon stock option exercises | 423 | 392 | |||||||
| Principal payments on finance leases | (14) | (14) | |||||||
| Payment of offering costs | - | (155) | |||||||
| Issuance of common stock in ATM offering | - | 7,782 | |||||||
| Net cash provided by financing activities | 409 | 8,005 | |||||||
| Net increase (decrease) in cash and cash equivalents and restricted cash | 175,104 | (26,192) | |||||||
| Cash and cash equivalents and restricted cash, beginning of period | 162,657 | 161,066 | |||||||
| Cash and cash equivalents and restricted cash, end of period | $ | 337,761 | $ | 134,874 | |||||
| Supplemental disclosure of cash flow and noncash information | |||||||||
| Cash paid for income taxes | $ | 139 | $ | 180 | |||||
| Supplemental disclosure of non-cash investing and financing activities | |||||||||
| Purchases of property and equipment in accounts payable | 13 | 501 | |||||||
| Purchases of property and equipment in accrued liabilities | 25 | 282 | |||||||
| Acquisition of right of use assets - operating leases, contingency resolution | - | 2,848 |
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
| Three Months Ended | |||||||||||
| March 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| (in thousands, except per share data) | |||||||||||
| Net loss (GAAP) | $ | (59,808) | $ | (54,724) | |||||||
| Income tax expense | 28 | 456 | |||||||||
| Gain on equity investment | - | - | |||||||||
| Change in fair value | 13,095 | (8,137) | |||||||||
| Non-GAAP net loss | $ | (46,685) | $ | (62,405) | |||||||
| Non-GAAP net loss per share of common and limited common stockholders, basic and diluted | $ | (0.64) | $ | (0.86) | |||||||
| Weighted average shares used to compute non-GAAP net loss per share of common and limited common stockholders, basic and diluted | 73,057,916 | 72,291,134 |